# A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

> **NCT01871727** · PHASE3 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 112 (actual)

## Conditions studied

- Persistent or Recurrent Cutaneous T-Cell Lymphoma

## Interventions

- **DRUG:** E7777 9 mcg/kg

## Key facts

- **NCT ID:** NCT01871727
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-30
- **Primary completion:** 2021-12-06
- **Final completion:** 2021-12-14
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2024-11-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01871727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01871727, "A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01871727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*